Carlos Fraga

List of Publications by Year in descending order

228 papers	7,608 citations	81839 39 h-index	64755 79 g-index
244 all docs	244 docs citations	244 times ranked	9298 citing authors

#	Article	IF	Citations
1	New 4-nitro-imidazole-N-glycinyl-hydrazones designed as trypanocidal analogues of benznidazole. Letters in Drug Design and Discovery, 2022, 19, .	0.4	1
2	Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositolâ€3â€kinase (PI3K): Current and Future Prospects. ChemMedChem, 2021, 16, 448-457.	1.6	16
3	Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer. Pharmaceuticals, 2021, 14, 387.	1.7	8
4	Introduction to celebrating Latin American talent in chemistry. RSC Advances, 2021, 11, 40216-40219.	1.7	1
5	Structureâ€“property relationship studies of 3-acyl-substituted furans: the serendipitous identification and characterization of a new non-classical hydrogen bond donor moiety. New Journal of Chemistry, 2020, 44, 10994-11005.	1.4	3
6	Therapeutic Effects of Anti-Inflammatory N-Acylhydrazones in the Resolution of Experimental Colitis. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 420-427.	1.3	3
7	Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. Medicinal Research Reviews, 2020, 40, 2177-2211.	5.0	38
8	New 2-amino-pyridinyl-N-acylhydrazones: Synthesis and identification of their mechanism of anti-inflammatory action. Biomedicine and Pharmacotherapy, 2020, 123, 109739.	2.5	9
9	Design, Synthesis, and Pharmacological Evaluation of Firstâ€inâ€Class Multitarget Nâ€Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors. ChemMedChem, 2020, 15, 539-551.	1.6	28
10	Synthesis and trypanocidal activity of novel pyridinyl-1,3,4-thiadiazole derivatives. Biomedicine and Pharmacotherapy, 2020, 127, 110162.	2.5	11
11	Editorial: Oxidative Stress: How Has It Been Considered in the Design of New Drug Candidates for Neurodegenerative Diseases?. Frontiers in Pharmacology, 2020, 11, 609274.	1.6	3
12	HÃ•ALGO NOVO NO RECONHECIMENTO MOLECULAR APLICADO Ã€ QUÃMICA MEDICINAL?. Quimica Nova, 2020, , .	0.3	4
13	Identification of Novel Functionalized Carbohydrazonamides Designed as Chagas Disease Drug Candidates. Medicinal Chemistry, 2020, 16, 774-783.	0.7	1
14	Investigating the Molecular Basis for the Selective Inhibition of Aldehyde Dehydrogenase 2 by the Isoflavonoid Daidzin. CNS and Neurological Disorders - Drug Targets, 2020, 19, 437-447.	0.8	1
15	Abstract P091: New Rho-kinase Inhibitors Reduce Cardiac Dysfunction And Vascular Remodeling In Pulmonary Hypertension In Rats. Hypertension, 2020, 76, .	1.3	0
16	Strategies and Tactics in Medicinal Chemistry. Current Topics in Medicinal Chemistry, 2019, 19, 1677-1678.	1.0	0
17	Gastroprotective effects of N-acylarylhydrazone derivatives on ethanol-induced gastric lesions in mice are dependent on the NO/cGMP/KATP pathway. Biochemical Pharmacology, 2019, 169, 113629.	2.0	14
18	Meet Our Section Editor. Current Topics in Medicinal Chemistry, 2019, 18, 2133-2135.	1.0	0

#	Article	IF	Citations
19	Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases. Pharmaceuticals, 2019, 12, 69.	1.7	53
20	Evaluation of Functional Selectivity of Haloperidol, Clozapine, and LASSBio-579, an Experimental Compound With Antipsychotic-Like Actions in Rodents, at G Protein and Arrestin Signaling Downstream of the Dopamine D2 Receptor. Frontiers in Pharmacology, 2019, 10, 628.	1.6	2
21	The Chalcone Lonchocarpin Inhibits Wnt/Î²-Catenin Signaling and Suppresses Colorectal Cancer Proliferation. Cancers, 2019, 11, 1968.	1.7	37
22	The Use of Conformational Restriction in Medicinal Chemistry. Current Topics in Medicinal Chemistry, 2019, 19, 1712-1733.	1.0	26
23	New analogs of LASSBioâ€1829Cl with antiâ€inflammatory properties. FASEB Journal, 2019, 33, lb41.	0.2	0
24	Design, Synthesis and Pharmacological Evaluation of Novel Antiinflammatory and Analgesic O-Benzyloxime Compounds Derived From Natural Eugenol. Letters in Drug Design and Discovery, 2019, 16, 1157-1166.	0.4	0
25	Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40). Chemical Biology and Drug Design, 2018, 91, 668-680.	1.5	11
26	Theoretical and experimental characterization of 1,4-Nâ‹¯S Ïƒ-hole intramolecular interactions in bioactive N-acylhydrazone derivatives. New Journal of Chemistry, 2018, 42, 497-505.	1.4	15
27	Discovery of naphthylâ€Nâ€acylhydrazone p38Î± MAPK inhibitors with in vivo antiâ€inflammatory and antiâ€TNFâ€Î± activity. Chemical Biology and Drug Design, 2018, 91, 391-397.	1.5	22
28	Design, Synthesis, Experimental and Theoretical Characterization of a New Multitarget 2-Thienyl-N-Acylhydrazone Derivative. Pharmaceuticals, 2018, 11, 119.	1.7	7
29	Modeling zincâ€oxygen coordination in histone deacetylase: A comparison of semiempirical methods performance. International Journal of Quantum Chemistry, 2018, 118, e25720.	1.0	5
30	Cardioprotection Induced by Activation of GPER in Ovariectomized Rats With Pulmonary Hypertension. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1158-1166.	1.7	17
31	Synthesis and pharmacological evaluation of novel isoquinoline N-sulphonylhydrazones designed as ROCK inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1181-1193.	2.5	9
32	N-Acylhydrazones as drugs. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2797-2806.	1.0	140
33	The novel piperazine-containing compound LQFM018: Necroptosis cell death mechanisms, dopamine D4 receptor binding and toxicological assessment. Biomedicine and Pharmacotherapy, 2018, 102, 481-493.	2.5	12
34	Eine ungewÃ¶hnliche intramolekulare Halogenbindung fÃ¼hrt zu konformationeller Selektion. Angewandte Chemie, 2018, 130, 10120-10126.	1.6	0
35	An Unusual Intramolecular Halogen Bond Guides Conformational Selection. Angewandte Chemie - International Edition, 2018, 57, 9970-9975.	7.2	12
36	Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. PLoS ONE, 2018, 13, e0195047.	1.1	8

#	Article	IF	Citations
37	NF-Î²B-IKKÎ² Pathway as a Target for Drug Development: Realities, Challenges and Perspectives. Current Drug Targets, 2018, 19, 1933-1942.	1.0	43
38	Different molecular conformations in the crystal structures of three 5-nitroimidazolyl derivatives. Acta Crystallographica Section E: Crystallographic Communications, 2018, 74, 380-384.	0.2	0
39	LASSBio-1422: a new molecular scaffold with efficacy in animal models of schizophrenia and disorders of attention and cognition. Behavioural Pharmacology, 2017, 28, 48-62.	0.8	12
40	ROCK inhibition with Fasudil induces beta-catenin nuclear translocation and inhibits cell migration of MDA-MB 231 human breast cancer cells. Scientific Reports, 2017, 7, 13723.	1.6	35
41	Design, Synthesis, and Trypanocidal Activity of Novel 5-Nitroimidazolyl O -Benzyloxime Ethers. Journal of Heterocyclic Chemistry, 2017, 54, 3626-3631.	1.4	4
42	LASSBio-897 Reduces Lung Injury Induced by Silica Particles in Mice: Potential Interaction with the A2A Receptor. Frontiers in Pharmacology, 2017, 8, 778.	1.6	6
43	Adenosine A_{2A} receptor agonist prevents cardiac remodeling and dysfunction in spontaneously hypertensive male rats after myocardial infarction. Drug Design, Development and Therapy, 2017, Volume11, 553-562.	2.0	31
44	LASSBioâ€1829 Hydrochloride: Development of a New Orally Active Nâ€Acylhydrazone IKK2 Inhibitor with Antiâ€inflammatory Properties. ChemMedChem, 2016, 11, 234-244.	1.6	7
45	Treatment with Adenosine Receptor Agonist Ameliorates Pain Induced by Acute and Chronic Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 315-323.	1.3	18
46	LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model. Behavioural Pharmacology, 2016, 27, 339-349.	0.8	7
47	Filtering promiscuous compounds in early drug discovery: is it a good idea?. Drug Discovery Today, 2016, 21, 868-872.	3.2	73
48	Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 655-670.	2.9	86
49	LASSBio-1425, an analog of thalidomide, decreases triglyceride and increases HDL cholesterol levels by inhibition of TNF-Î± production. International Journal of Cardiology, 2016, 202, 497-499.	0.8	9
50	Discovery of Novel Orally Active Tetrahydro-Naphthyl-N-Acylhydrazones with In Vivo Anti-TNF-Î± Effect and Remarkable Anti-Inflammatory Properties. PLoS ONE, 2016, 11, e0156271.	1.1	22
51	Beyond the Selective Inhibition of Histone Deacetylase 6. Mini-Reviews in Medicinal Chemistry, 2016, 16, 1175-1184.	1.1	17
52	Understanding the Structural Basis of ALDH-2 Inhibition by Molecular Docking. Medicinal Chemistry, 2016, 12, 506-512.	0.7	2
53	Structural characterization of LASSBio-1289: a new vasoactive N-methyl-N-acylhydrazone derivative. CrystEngComm, 2015, 17, 165-173.	1.3	10
54	Novel Agonist of Adenosine Receptor Induces Relaxation of Corpus Cavernosum in Guinea Pigs: An InÂVitro and InÂVivo Study. Urology, 2015, 85, 1214.e17-1214.e21.	0.5	4

#	Article	IF	Citations
55	Partial agonism and fast dissociation of LASSBio-579 at dopamine D2 receptor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 62, 1-6.	2.5	4
56	In vivo effect of LASSBio-785, a lipid-lowering and anti-inflammatory agent, on cardiac Ca2+-ATPases from hypercholesterolemic rats. International Journal of Cardiology, 2015, 201, 282-284.	0.8	2
57	Synthesis and Biological Evaluation of Pyrazolo[3,4-<i>b</i>]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors. Medicinal Chemistry, 2015, 11, 342-353.	0.7	6
58	Revisiting the Message-Address Concept in Medicinal Chemistry. Revista Virtual De Quimica, 2015, 7, .	0.1	0
59	BUBONIC PLAGUE: HISTORICAL ASPECTS AND THERAPY. Military Medical Science Letters (Vojenske) Tj ETQq1 1 0.784314 rgBT /Over	0.2	1
60	Novel Potent Imidazo[1,2-a]pyridine-N-Glycinyl-Hydrazone Inhibitors of TNF-Î± Production: In Vitro and In Vivo Studies. PLoS ONE, 2014, 9, e91660.	1.1	16
61	Crystal structures of 1-hydroxylimidazole and imidazole 1-oxide derivatives. Zeitschrift Fur Kristallographie - Crystalline Materials, 2014, 229, 709-722.	0.4	7
62	Vasodilator and antihypertensive effects of a novel <scp>N</scp>â€acylhydrazone derivative mediated by the inhibition of <scp>L</scp>â€type Ca²⁺ channels. Fundamental and Clinical Pharmacology, 2014, 28, 29-41.	1.0	8
63	Acylhydrazone derivatives: a patent review. Expert Opinion on Therapeutic Patents, 2014, 24, 1161-1170.	2.4	53
64	N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity. International Journal of Cardiology, 2014, 173, 154-162.	0.8	36
65	N-acylhydrazone improves exercise intolerance in rats submitted to myocardial infarction by the recovery of calcium homeostasis in skeletal muscle. Life Sciences, 2014, 94, 30-36.	2.0	10
66	Antiprotozoal Activity of (E)-Cinnamic N-Acylhydrazone Derivatives. Molecules, 2014, 19, 20374-20381.	1.7	13
67	LASSBio-1135: A Dual TRPV1 Antagonist and Anti-TNF-Alpha Compound Orally Effective in Models of Inflammatory and Neuropathic Pain. PLoS ONE, 2014, 9, e99510.	1.1	13
68	Structure Determination of LASSBio-1289: A New Antihypertensive Lead-Compound. Acta Crystallographica Section A: Foundations and Advances, 2014, 70, C1830-C1830.	0.0	0
69	Biotransformation of LASSBio-579 and pharmacological evaluation of p -hydroxylated metabolite a N -phenylpiperazine antipsychotic lead compound. European Journal of Medicinal Chemistry, 2013, 62, 214-221.	2.6	14
70	A novel CaÂ²+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension. European Journal of Pharmacology, 2013, 702, 316-322.	1.7	14
71	P.3.c.001 Pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579. European Neuropsychopharmacology, 2013, 23, S453.	0.3	0
72	Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579. European Journal of Medicinal Chemistry, 2013, 66, 122-134.	2.6	25

#	Article	IF	Citations
73	Beneficial effects of a novel agonist of the adenosine <scp>A_{2A}</scp> receptor on monocrotalineâ€induced pulmonary hypertension in rats. British Journal of Pharmacology, 2013, 169, 953-962.	2.7	37
74	New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. Behavioural Brain Research, 2013, 237, 86-95.	1.2	26
75	Antihyperalgesic effects of a novel muscarinic agonist (<scp>LASSB</scp>ioâ€873) in spinal nerve ligation in rats. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 404-411.	0.9	8
76	Anti-atherogenic Effects of a New Thienylacylhydrazone Derivative, LASSBio-788, in Rats Fed a Hypercholesterolemic Diet. Journal of Pharmacological Sciences, 2013, 123, 47-57.	1.1	15
77	Characterization of Amide Bond Conformers for a Novel Heterocyclic Template of N-acylhydrazone Derivatives. Molecules, 2013, 18, 11683-11704.	1.7	82
78	Article Synthesis and Trypanocidal Activity of Novel 2,4,5-Triaryl-N-Hydroxylimidazole Derivatives. Molecules, 2013, 18, 3445-3457.	1.7	21
79	Impairment of locomotor activity induced by the novelN-acylhydrazone derivatives LASSBio-785 and LASSBio-786 in mice. Brazilian Journal of Medical and Biological Research, 2013, 46, 263-269.	0.7	3
80	(2E)-Nâ€²-[(E)-Benzylidene]-3-phenylprop-2-enohydrazide from synchrotron radiation. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o2255-o2256.	0.2	2
81	(2E)-Nâ€²-[(E)-2-Hydroxybenzylidene]-3-phenylprop-2-enohydrazide. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o2253-o2254.	0.2	2
82	Novel furfurylidene N-acylhydrazones derived from natural safrole: discovery of LASSBio-1215, a new potent antiplatelet prototype. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 101-109.	2.5	6
83	Phenylpiperazine derivatives: a patent review (2006 â€“ present). Expert Opinion on Therapeutic Patents, 2012, 22, 1169-1178.	2.4	21
84	Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 7525-7545.	2.9	105
85	Design and synthesis of new (E)-cinnamic N-acylhydrazones as potent antitrypanosomal agents. European Journal of Medicinal Chemistry, 2012, 54, 512-521.	2.6	65
86	Antihypertensive profile of 2-thienyl-3,4-methylenedioxybenzoylhydrazone isÂmediated by activation of the A2A adenosine receptor. European Journal of Medicinal Chemistry, 2012, 55, 49-57.	2.6	36
87	Discovery of Novel Orally Active Anti-Inflammatory N-Phenylpyrazolyl-N-Glycinyl-Hydrazone Derivatives That Inhibit TNF-Î± Production. PLoS ONE, 2012, 7, e46925.	1.1	21
88	Molecular docking and molecular dynamic studies of semi-synthetic piperidine alkaloids as acetylcholinesterase inhibitors. Journal of the Brazilian Chemical Society, 2012, 23, 163-170.	0.6	6
89	Synthesis and characterization of the atropisomeric relationships of a substituted Nâ€phenylâ€bipyrazole derivative with antiâ€inflammatory properties. Chirality, 2012, 24, 463-470.	1.3	2
90	Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone. Journal of Molecular Modeling, 2012, 18, 2065-2078.	0.8	23

#	Article	IF	Citations
91	Molecular Modeling Studies ofYersinia pestisDihydrofolate Reductase. Journal of Biomolecular Structure and Dynamics, 2011, 29, 351-367.	2.0	12
92	The Methylation Effect in Medicinal Chemistry. Chemical Reviews, 2011, 111, 5215-5246.	23.0	671
93	Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-Adrenergic receptor blocking properties. European Journal of Medicinal Chemistry, 2011, 46, 3000-3012.	2.6	32
94	CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes. European Journal of Medicinal Chemistry, 2011, 46, 349-355.	2.6	7
95	Structure-based design and biological profile of (E)-N-(4-Nitrobenzylidene)-2-naphthohydrazide, a novel small molecule inhibitor of Ii°B kinase-Î². European Journal of Medicinal Chemistry, 2011, 46, 1245-1253.	2.6	22
96	Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LCâ€“MS/MS: Application for a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 1024-1030.	1.4	7
97	MAOS and Medicinal Chemistry: Some Important Examples from the Last Years. Molecules, 2011, 16, 9274-9297.	1.7	18
98	The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders II: Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 251-270.	0.8	93
99	The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 239-250.	0.8	32
100	Discovery of Dual Chemotherapy Drug Candidates Designed by Molecular Hybridization. Current Enzyme Inhibition, 2010, 6, 171-182.	0.3	13
101	Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. Journal of Pharmacy and Pharmacology, 2010, 60, 699-707.	1.2	33
102	Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorganic and Medicinal Chemistry, 2010, 18, 1925-1935.	1.4	57
103	Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition. European Journal of Pharmacology, 2010, 638, 5-12.	1.7	25
104	Characterization of the conformational ensemble from bioactive N-acylhydrazone derivatives. Journal of Molecular Graphics and Modelling, 2010, 28, 446-454.	1.3	12
105	Design of new dopamine D2 receptor ligands: Biosynthesis and pharmacological evaluation of the hydroxylated metabolite of LASSBio-581. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2888-2891.	1.0	7
106	Microwave-assisted synthesis and structureâ€“activity relationships of neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 74-77.	1.0	39
107	Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3734-3736.	1.0	14
108	LASSBioâ€881: an Nâ€acylhydrazone transient receptor potential vanilloid subfamily type 1 antagonist orally effective against the hypernociception induced by capsaicin or partial sciatic ligation. British Journal of Pharmacology, 2010, 159, 1716-1723.	2.7	12

#	Article	IF	Citations
109	(2E)-Nâ€²-[(E)-4-Chlorobenzylidene]-3-phenylprop-2-enohydrazide monohydrate. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o2410-o2411.	0.2	4
110	Pharmacological Characterization of (3-Thienylidene)-3,4-Methylenedioxybenzoylhydrazide: A Novel Muscarinic Agonist With Antihypertensive Profile. American Journal of Hypertension, 2010, 23, 135-141.	1.0	19
111	LASSBio-294, A Compound With Inotropic and Lusitropic Activity, Decreases Cardiac Remodeling and Improves Ca2+ Influx Into Sarcoplasmic Reticulum After Myocardial Infarction. American Journal of Hypertension, 2010, 23, 1220-1227.	1.0	23
112	Cardiovascular effects induced by N-(4'-dihydro)-piperoylthiomorpholine in normotensive rats. Journal of Pharmacy and Pharmacology, 2010, 62, 1794-1800.	1.2	0
113	In Vitro and In Vivo Activities of 1,3,4-Thiadiazole-2-Arylhydrazone Derivatives of Megazol against Trypanosoma cruzi. Antimicrobial Agents and Chemotherapy, 2010, 54, 2023-2031.	1.4	34
114	Antimycobacterial Profile of 5-phenyl-1,3,4-thiadiazole-2-arylhydrazone Derivatives. Letters in Drug Design and Discovery, 2010, 7, 606-609.	0.4	5
115	Analysis of the regional air passenger transport system in Brazil: some aspects of its evolution and diagnosis. International Journal of Sustainable Development and Planning, 2010, 5, 141-149.	0.3	1
116	ExtraÃ§Ã£o e purificaÃ§Ã£o de fÃ¡rmacos anti-inflamatÃ³rios nÃ£o esteroidais ciclo-oxigenase-2 seletivos. Quimica Nova, 2009, 32, 1324-1328.	0.3	5
117	5-Phenyl-2-(benzalhydrazonyl)-1,3,4-thiadiazoles, potential trypanocidal agents: consistent dimer formation via Nâ€“H Â· Â· Â· N intermolecular hydrogen bonds. Zeitschrift FÃ¼r Kristallographie, 2009, 224, 598-606.	1.1	12
118	Sedation and antinociception induced by a new pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivative (LASSBio-873) is modulated by activation of muscarinic receptors. Pharmacology Biochemistry and Behavior, 2009, 94, 70-74.	1.3	19
119	Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives. European Journal of Medicinal Chemistry, 2009, 44, 4004-4009.	2.6	71
120	Synthesis, pharmacological evaluation and docking studies of new sulindac analogues. European Journal of Medicinal Chemistry, 2009, 44, 1959-1971.	2.6	10
121	Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors. European Journal of Medicinal Chemistry, 2009, 44, 2482-2496.	2.6	7
122	Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorganic and Medicinal Chemistry, 2009, 17, 74-84.	1.4	187
123	Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: Orally effective anti-inflammatory drug candidates. Bioorganic and Medicinal Chemistry, 2009, 17, 1125-1131.	1.4	35
124	Synthesis and analgesic profile of conformationally constrained N-acylhydrazone analogues: Discovery of novel N-arylideneamino quinazolin-4(3H)-one compounds derived from natural safrole. Bioorganic and Medicinal Chemistry, 2009, 17, 6517-6525.	1.4	24
125	Design, synthesis and analgesic properties of novel conformationally-restricted N-acylhydrazones (NAH). Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4963-4966.	1.0	48
126	Structural insights into IKKÎ² inhibition by natural products staurosporine and quercetin. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6907-6910.	1.0	13

#	Article	IF	Citations
127	Drug hybridization strategies: before or after lead identification?. Expert Opinion on Drug Discovery, 2009, 4, 605-609.	2.5	61
128	From Nature to Drug Discovery: The Indole Scaffold as a ‘Privileged Structure’. Mini-Reviews in Medicinal Chemistry, 2009, 9, 782-793.	1.1	498
129	Synthesis and anti-platelet activity of novel arylsulfonateâ€“acylhydrazone derivatives, designed as antithrombotic candidates. European Journal of Medicinal Chemistry, 2008, 43, 348-356.	2.6	60
130	NSAIDs revisited: Putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARÎ³). European Journal of Medicinal Chemistry, 2008, 43, 1918-1925.	2.6	7
131	Studies toward the structural optimization of new brazilizone-related trypanocidal 1,3,4-thiadiazole-2-arylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 413-421.	1.4	40
132	CNS-selective noncompetitive cholinesterase inhibitors derived from the natural piperidine alkaloid (â˜)-spectaline. European Journal of Pharmacology, 2008, 580, 339-349.	1.7	34
133	Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581. Pharmacology Biochemistry and Behavior, 2008, 89, 23-30.	1.3	14
134	Microbial reduction of alpha-substituted-alpha-acetyl-gamma-butyrolactones. Catalysis Communications, 2008, 9, 1782-1786.	1.6	7
135	Improved Solventâ€Free Dakin Oxidation Protocol. Synthetic Communications, 2008, 38, 784-788.	1.1	27
136	Antinociceptive Profile of 2,3,6-Trisubstituted Piperidine Alkaloids: 3-O-Acetyl-spectaline and Semi-synthetic Derivatives of (-)-Spectaline. Chemical and Pharmaceutical Bulletin, 2008, 56, 407-412.	0.6	23
137	1-Methyl-7-(4-nitrophenyl)-3-phenylpyrazolo[3,4-b]pyrrolo[3,4-d]pyridine-6,8(3H,7H)-dione. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o2356-o2356.	0.2	0
138	New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs. Current Drug Therapy, 2008, 3, 1-13.	0.2	19
139	Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes. Current Medicinal Chemistry, 2007, 14, 1829-1852.	1.2	930
140	Privileged Structures: A Useful Concept for the Rational Design of New Lead Drug Candidates. Mini-Reviews in Medicinal Chemistry, 2007, 7, 1108-1119.	1.1	266
141	The Molecular Basis of COX-2 Versus COX-1 Selectivity of Lumiracoxib by Molecular Docking Studies. Letters in Drug Design and Discovery, 2007, 4, 422-425.	0.4	3
142	Atropoisomerismo: o efeito da quiralidade axial em substÃ¢ncias bioativas. Quimica Nova, 2007, 30, 125-135.	0.3	15
143	High performance liquid chromatography method for quantification of the N-phenylpiperazine derivative LASSBio-579 in rat plasma. Quimica Nova, 2007, 30, 1919-1922.	0.3	1
144	Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 2421-2433.	1.4	59

#	Article	IF	Citations
145	Development and validation of a LC-MS/MS method with electrospray ionization for determination of LASSBio-579 in rat plasma. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 677-682.	1.4	7
146	Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2006, 5, 79-95.	1.1	5
147	Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFÎ± modulators. Bioorganic and Medicinal Chemistry, 2006, 14, 6874-6885.	1.4	16
148	Design and synthesis of 3,4-methylenedioxy-6-nitrophenoxyacetylhydrazone derivatives obtained from natural safrole: New lead-agents with analgesic and antipyretic properties. Bioorganic and Medicinal Chemistry, 2006, 14, 7924-7935.	1.4	80
149	Design, synthesis, and pharmacological evaluation of new neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives with in vivo hypnotic and analgesic profile. Bioorganic and Medicinal Chemistry, 2006, 14, 632-640.	1.4	41
150	Microbial reduction of Î±-acetyl-Î³-butyrolactone. Tetrahedron: Asymmetry, 2006, 17, 984-988.	1.8	14
151	Medicinal Chemistry of N-Acylhydrazones: New Lead-Compounds of Analgesic, Antiinflammatory and Antithrombotic Drugs. Current Medicinal Chemistry, 2006, 13, 167-198.	1.2	95
152	Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues. Bioorganic and Medicinal Chemistry, 2005, 13, 3431-3437.	1.4	87
153	New selective acetylcholinesterase inhibitors designed from natural piperidine alkaloids. Bioorganic and Medicinal Chemistry, 2005, 13, 4184-4190.	1.4	48
154	A proposed molecular basis for the selective resveratrol inhibition of the PGHS-1 peroxidase activity. Bioorganic and Medicinal Chemistry, 2005, 13, 5981-5985.	1.4	2
155	Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1169-1172.	1.0	70
156	Evaluating the prophylactic potential of the phtalimide derivative LASSBio 552 on allergen-evoked inflammation in rats. European Journal of Pharmacology, 2005, 511, 219-227.	1.7	2
157	Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. European Journal of Pharmaceutical Sciences, 2005, 26, 194-202.	1.9	11
158	Electrospray ionization mass and tandem mass spectra of a series ofN-pyrazolylmethyl andN-triazolylmethylN-phenylpiperazines: new dopaminergic ligands with potential antipsychotic properties. Journal of Mass Spectrometry, 2005, 40, 815-820.	0.7	13
159	Synthesis and Antitrypanosomal Profile of New Functionalized 1,3,4-Thiadiazole-2-arylhydrazone Derivatives, Designed as Non-mutagenic Megazol Analogues.. ChemInform, 2005, 36, no.	0.1	0
160	The molecular basis for coxib inhibition of p38Î± MAP kinase. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3506-3509.	1.0	13
161	Design, Synthesis and Pharmacological Evaluation of New Nonsteroidal Antiinflammatory 1,3,4-Thiadiazole Derivatives. Letters in Drug Design and Discovery, 2005, 2, 62-67.	0.4	19
162	A questÃ£o da inovaÃ§Ã£o em fÃ¡rmacos no Brasil: proposta de criaÃ§Ã£o do programa nacional de fÃ¡rmacos (Pronfar). Quimica Nova, 2005, 28, S56-S63.	0.3	1

#	Article	IF	Citations
163	New Anti-Alzheimer Drugs from Biodiversity: The Role of the Natural Acetylcholinesterase Inhibitors. Mini-Reviews in Medicinal Chemistry, 2005, 5, 915-926.	1.1	39
164	Cysteinyl Leukotriene Receptor Antagonists and Thromboxane Synthase Inhibitors: New Targets to Treat Asthma. Current Medicinal Chemistry Anti-inflammatory & Anti-allergy Agents, 2004, 3, 9-18.	0.4	0
165	Esquizofrenia: quarenta anos da hipÃ³tese dopaminÃ©rgica sob a Ã³tica da QuÃmica Medicinal. Quimica Nova, 2004, 27, 447-455.	0.3	5
166	Agentes dopaminÃ©rgicos e o tratamento da disfunÃ§Ã£o erÃ©til. Quimica Nova, 2004, 27, 949-957.	0.3	2
167	New optimized piperamide analogues with potent in vivo hypotensive properties. European Journal of Pharmaceutical Sciences, 2004, 23, 363-369.	1.9	26
168	Studies on diastereoselective reduction of cyclic Î²-ketoesters with boron hydrides. Part 4: The reductive profile of functionalized cyclohexanone derivatives. Tetrahedron, 2004, 60, 2745-2755.	1.0	28
169	New class of potent antinociceptive and antiplatelet 10H-phenothiazine-1-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2004, 12, 3149-3158.	1.4	125
170	Synthesis and antitrypanosomal profile of new functionalized 1,3,4-thiadiazole-2-arylhydrazone derivatives, designed as non-mutagenic megazol analogues. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5967-5970.	1.0	77
171	Produtos naturais como candidatos a fÃ¡rmacos Ãºteis no tratamento do Mal de Alzheimer. Quimica Nova, 2004, 27, 655-660.	0.3	26
172	Synthesis and Biological Evaluation of New Imidazo[1,2-a]pyridine Derivatives Designed as Mefloquine Analogues.. ChemInform, 2003, 34, no.	0.1	0
173	Synthesis and Pharmacological Evaluation of Novel Antinociceptive N-Substituted-phenylimidazolyl-4-acylhydrazone Derivatives.. ChemInform, 2003, 34, no.	0.1	0
174	Validated HPLC method for determination of LASSBio-581, a new heterocyclic N-phenylpiperazine derivative, in rat plasma. Journal of Pharmaceutical and Biomedical Analysis, 2003, 33, 1127-1133.	1.4	2
175	Antiplatelet properties of novel N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2003, 11, 2051-2059.	1.4	168
176	Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands. Bioorganic and Medicinal Chemistry, 2003, 11, 4807-4813.	1.4	67
177	Chiral separation of Î³-butyrolactone derivatives by gas chromatography on 2,3-di-O-methyl-6-O-tert.-butyldimethylsilyl-Î²-cyclodextrin. Journal of Chromatography A, 2003, 985, 321-331.	1.8	11
178	Design, Synthesis, and Pharmacological Profile of Novel Fused Pyrazolo[4,3-d]pyridine and Pyrazolo[3,4-b][1,8]naphthyridine Isosteres:Â A New Class of Potent and Selective Acetylcholinesterase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 1144-1152.	2.9	101
179	Novas estratÃ©gias terapÃªuticas para o tratamento da depressÃ£o: uma visÃ£o da quÃmica medicinal. Quimica Nova, 2003, 26, 347-358.	0.3	10
180	STUDIES ON THE DIASTEREO- SELECTIVE REDUCTION OF 2-ACETYL-2-ALKYL- Î³-BUTYROLACTONES WITH BORON HYDRIDES*. Synthetic Communications, 2002, 32, 505-526.	1.1	10

#	Article	IF	Citations
181	Selective PGHS-2 Inhibitors: A Rational Approach for Treatment of theInflammation. Current Medicinal Chemistry, 2002, 9, 849-867.	1.2	20
182	A quÃmica medicinal de N-acilidrazonas: novos compostos-protÃ³tipos de fÃ¡rmacos analgÃ©sicos, antiinflamatÃ³rios e anti-trombÃ³ticos. Quimica Nova, 2002, 25, 129-148.	0.3	42
183	Agentes antiasmÃ¡ticos modernos: antagonistas de receptores de leucotrienos cisteÃnicos. Quimica Nova, 2002, 25, 825-834.	0.3	1
184	Synthesis and pharmacological evaluation of novel antinociceptive N-substituted-phenylimidazolyl-4-acylhydrazone derivatives. Il Farmaco, 2002, 57, 999-1007.	0.9	22
185	Synthesis and biological evaluation of new imidazo[1,2-a]pyridine derivatives designed as mefloquine analogues. Il Farmaco, 2002, 57, 825-832.	0.9	23
186	Design, synthesis and pharmacological evaluation of novel pyrazolo[3,4-b]thieno[2,3-d]pyridine acid derivatives: a new class of anti-inflammatory and anti-platelet agents. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 9-12.	1.0	16
187	Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1533-1535.	1.0	24
188	Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorganic and Medicinal Chemistry, 2002, 10, 3067-3073.	1.4	174
189	New isoxazole derivatives designed as nicotinic acetylcholine receptor ligand candidates. European Journal of Medicinal Chemistry, 2002, 37, 163-170.	2.6	37
190	Highly diastereoselective mercury-mediated synthesis of functionalized 2-azabicyclo[3.3.0]octane derivatives. Tetrahedron Letters, 2002, 43, 1607-1611.	0.7	12
191	Synthesis and pharmacological evaluation of a new 2-azabicyclo[3.3.0]octane derivative. Journal of the Brazilian Chemical Society, 2001, 12, 408.	0.6	7
192	O renascimento de um fÃ¡rmaco: talidomida. Quimica Nova, 2001, 24, 683.	0.3	6
193	SYNTHESIS OF NATURAL AMIDE ALKALOID PIPERDARDINE AND A NEW BIOACTIVE ANALOGUEâ€. Synthetic Communications, 2001, 31, 117-123.	1.1	10
194	Synthesis of Functionalized Î³-Spirolactone and 2-Oxabicyclo[3.3.0]octane Derivatives from Nucleophilic Oxirane Ring Opening. Tetrahedron, 2000, 56, 5289-5295.	1.0	8
195	Design and Synthesis of Novel Potent Antinociceptive Agents: Methyl-imidazolyl N-Acylhydrazone Derivatives. Bioorganic and Medicinal Chemistry, 2000, 8, 2243-2248.	1.4	47
196	Synthesis and analgesic activity of novel N-acylarylhydrazones and isosters, derived from natural safrole##This paper represents contribution # 36 of the LASSBio, UFRJ (Br.) (LASSBio,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142 Td (htt Chemistry, 2000, 35, 187-203.	2.6	195
197	Synthesis and pharmacological evaluation of novel heterotricyclic acylhydrazone derivatives, designed as PAF antagonists. European Journal of Pharmaceutical Sciences, 2000, 11, 285-290.	1.9	37
198	A possible molecular mechanism for the inhibition of cysteine proteases by salicylaldehyde N-acylhydrazones and related compounds. Computational and Theoretical Chemistry, 2000, 505, 11-17.	1.5	36

#	Article	IF	Citations
199	O-Alkylation of Bioactive Phthalimide Derivatives Under Microwave Irradiation in Dry Media. Synthetic Communications, 2000, 30, 3291-3306.	1.1	11
200	Chiral Gas Chromatographic Separation of 2-Oxabicyclo[3.3.0]octane Derivatives and Their Synthetic Precursors. Analytical Chemistry, 2000, 72, 3056-3062.	3.2	5
201	New antithrombotic aryl-sulfonylthiosemicarbazide derivatives synthesized from natural safrole. Journal of the Brazilian Chemical Society, 1999, 10, 421-428.	0.6	9
202	SYNTHESIS OF NEW ISOSTERIC HETEROTRICYCLIC DERIVATIVES: PYRAZOLO[3,4-b]THIENO[3,2-e]PYRIDINE, PYRAZOLO[3,4-b]PYRROLO[3,2-e]PYRIDINE AND FURO[2,3-b]PYRAZOLO[4,3-e]PYRIDINE. Heterocyclic Communications, 1999, 5, .	0.6	0
203	Synthesis and antiplatelet evaluation of novel aryl-sulfonamide derivatives, from natural safrole. Pharmaceutica Acta Helvetiae, 1999, 73, 281-292.	1.2	16
204	Studies on antiplatelet agents from natural safrole. Pharmaceutica Acta Helvetiae, 1999, 74, 19-28.	1.2	5
205	Synthesis and analgesic profile of novel N-containing heterocycle derivatives: arylidene 3-phenyl-1,2,4-oxadiazole-5-carbohydrazide. Il Farmaco, 1999, 54, 747-757.	0.9	31
206	Proposal of a new PAF pharmacophoric map by the AM1 method. European Journal of Pharmaceutical Sciences, 1999, 8, 309-315.	1.9	1
207	Synthesis of Piperamides and New Analogues from Natural Safrole. Synthetic Communications, 1999, 29, 263-273.	1.1	10
208	A utilizaÃ§Ã£o do safrol, principal componente quÃmico do Ã³leo de sassafrÃ¡z, na sÃntese de substÂncias bioativas na cascata do Ã¡cido araquidÃ´nico: antiinflamatÃ³rios, analgÃ©sicos e anti-trombÃ³ticos. Quimica Nova, 1999, 22, 744-759.	0.3	37
209	Synthesis and pharmacological evaluation of a new class of bicyclic phospholipids, designed as platelet activating factor antagonists. Il Farmaco, 1998, 53, 327-336.	0.9	8
210	Synthesis and pharmacological evaluation of new flosulide analogues, synthesized from natural safrole. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 183-188.	1.0	23
211	Synthesis and antinociceptive properties of new structurally planned imidazo[1,2-a]pyridine 3-acylarylhydrazone derivatives. European Journal of Medicinal Chemistry, 1998, 33, 225-235.	2.6	61
212	Synthesis of New Benzylic Ethers of Oximes Derived from 1-Phenyl-pyrazole Compounds. Synthetic Communications, 1998, 28, 1299-1321.	1.1	6
213	Diastereomeric Analysis of Bioactive N-Phenylpyrazole-4-acylhydrazone Derivatives by High Resolution Gas Chromatography. Analytical Letters, 1998, 31, 719-732.	1.0	10
214	Studies on Diastereoselective Synthesis of 3-Vinyl-5-carbomethoxy-2-oxabicyclo[3.3.0]octane Derivatives Employing Palladium(II) Oxidative Cyclization. Heterocycles, 1998, 48, 2621.	0.4	8
215	Synthesis of new 1,2-Benzothiazin-3-one Derivatives Designed as Dual Cyclooxygenase-2 and 5-Lipooxygenase Inhibitors. Journal of the Brazilian Chemical Society, 1998, 9, 119-130.	0.6	7
216	Inibidores seletivos de prostaglandina endoperÃ³xido sintase-2 (PGHS-2): nova estratÃ©gia para o tratamento da inflamaÃ§Ã£o. Quimica Nova, 1998, 21, 761-771.	0.3	5

#	Article	IF	Citations
217	Reduction of 2-Alkyl-2-carbomethoxy-cyclopentanone Derivatives with Sodium Borohydride. II. The Elucidation of the Diastereoselective Control^a. Synthetic Communications, 1997, 27, 3241-3257.	1.1	18
218	SÃntese de Î²-cetoÃ©steres cÃclicos: novo procedimento para cicliza§Ãµes de Dieckmann empregando ALCL3 e trietilamina. Quimica Nova, 1997, 20, 435-437.	0.3	4
219	Improvement of enantioselective syntheses and chiral high resolution gas chromatographic analyses of (+)-2-allyl-2-carboethoxy-cyclopentanol. , 1997, 9, 321-324.		10
220	Design and Synthesis of a New 4-Oxa-8.OMEGA.-11-deoxy-5,6-dihydroprostacyclin Analogue.. Chemical and Pharmaceutical Bulletin, 1996, 44, 2157-2161.	0.6	11
221	Synthesis of condensed tricyclic pyrazolo[3,4-b]thieno[2,3-d]pyridine and related isostere derivatives. Journal of Heterocyclic Chemistry, 1996, 33, 309-313.	1.4	8
222	Enantiofacial selective reduction of 2-allyl-2-carboethoxy-cyclopentanone mediated by baker's yeast. , 1996, 8, 305-310.		17
223	Molecular modeling on platelet-activating factor (PAF) and new proposed PAF antagonists. International Journal of Quantum Chemistry, 1996, 60, 1069-1080.	1.0	5
224	Synthesis and Anti-Platelet Evaluation of New Tricyclic PAF Antagonists, Designed as Structurally Related to Hetrazepine Class - Web 2086. Journal of the Brazilian Chemical Society, 1996, 7, 247-256.	0.6	7
225	Semiempirical calculations on the mechanism of stereoselective NaBH4 reduction of 2-methoxycarbonyl-2-allyl-cyclopentanone. Computational and Theoretical Chemistry, 1995, 340, 193-199.	1.5	3
226	Studies Toward the Diastereoselective Reduction of 2-Alkoxycarbonyl-2-allyl-cyclopentanone Derivatives with Boron Hydrides. Synthetic Communications, 1995, 25, 1133-1144.	1.1	22
227	The synthesis of a new benzothiazine derivative, related to oxicams, synthesized from natural safrole. Journal of Heterocyclic Chemistry, 1992, 29, 1667-1669.	1.4	16
228	N-Acylhydrazone derivatives as potent histone deacetylase 6 inhibitors. , 0, , .		0